Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare

6. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders In Q3 2024: 61

Novo Nordisk A/S (NYSE:NVO) is one of the few companies in the world that has successfully made a splash with its weight loss drugs. Most of Cramer’s recent remarks for the firm have analyzed its product strength with respect to American weight loss drug giant Eli Lilly. Novo Nordisk A/S (NYSE:NVO)’s stock slipped by 17.8% in December after its weight loss drug trial missed investor expectations. They shed an additional 5.3% in January after its weight loss treatments were selected for Medicare price negotiations. Here’s what Cramer said about Novo Nordisk A/S (NYSE:NVO):

“[On the results of Novo’s latest drug trial] Okay, one and a half, it’s early. Remember it’s a one half trial. Now, you cane make these, you can finagle Lilly versus Novo. It’s hard, very hard to do actual comparisons because some are by forty eight weeks, some are shorter weeks. Some are bigger. . . what really matters? Boom, Eli Lilly’s scripts are way up. And if you’re looking at the fourth quarter, remember fourth quarter was a disappointment. David Ricks came on Mad Money, he came on our show. What did he say? He said we botched the launch. This is the beginning. Wolfe puts out the scripts, the numbers for Lilly were really good. And that’s what I’ve been waiting for. We can do this head to head of the phase one, the half. Forget that. Novo’s down so much, anything they put out . . .and this thing causes, you know it like makes you feel better. It wouldn’t matter. What matters is that Mounjaro and Zepbound weekly scripts are finally, finally doing good. And they have been not good. . . .”

“Lilly versus Novo this morning. Not one. Looked at every single data test that there is. Not one.”